Results 251 to 260 of about 8,460,931 (324)

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders. [PDF]

Nat Med
Bolsewig K, Bellomo G, Hok-A-Hin YS, Al Idrissi I, Vermunt L, Lleó A, Alcolea D, Sieben A, Engelborghs S, Simonsen AH, Hasselbalch SG, Bech S, Morrema THJ, Hoozemans JJM, Bol JGJM, van Alphen J, Gaetani L, Chiasserini D, Paolini Paoletti F, Parnetti L, Kang S, Lee YG, Jeon S, Lee A, Jeon S, Ye BS, Del Campo Milán M, van der Flier WM, van de Berg WDJ, Lemstra AW, Willemse EAJ, Teunissen CE.   +31 more
europepmc   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, Volume 13, Issue 9, Page 1780-1790, September 2026.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Quantitative susceptibility mapping reveals differences between subtypes of Lewy body dementia. [PDF]

Brain
Bhome R, Thomas GEC, Hannaway N, Dobreva I, Zarkali A, Shmueli K, Cole JH, Weil RS.   +7 more
europepmc   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

Association of mitochondrial genetic background with pS65-Ub in Lewy body disease. [PDF]

Acta Neuropathol
Tran NLK, Hou X, Heckman MG, Fiesel FC, Koga S, Watkins MM, Sledge HJ, Gibbs JR, Traynor BJ, Dalgard CL, Scholz SW, Dickson DW, Springer W, Ross OA.   +13 more
europepmc   +1 more source

Neurofluid Biomarker Sensors: Integrated Design Strategies From Molecular Recognition to Precision Neurological Diagnosis

Advanced Sensor Research, Volume 5, Issue 9, September 2026.
This review focuses on the principles and signal mechanisms of four types of neurofluid biomarker sensors (electrochemical, optical, mechanical, and multimodal), summarizes the detection strategies for biomarkers such as ions, neurotransmitters, metabolites, and inflammatory proteins and their applications in the diagnosis and treatment of neurological
Ting Li, Guoying Pan, Yuheng Wang, Xin Zou, Hui Yang   +4 more
wiley   +1 more source

Machine Learning‐Enhanced Ultrasensitive Immuno‐CRISPR Array Facilitates Early Diagnosis of Alzheimer's Disease by Detecting Multiple Plasma Biomarkers

Advanced Science, Volume 13, Issue 49, 3 September 2026.
This work presents a CRISPR‐based, ultrasensitive multiplex protein detection array capable of simultaneously analyzing six plasma biomarkers associated with Alzheimer's disease (AD). By integrating antibody‐mediated signal transduction, recombinase polymerase amplification, and spatially encoded CRISPR‐Cas12a, the system achieves detection sensitivity
Liding Zhang, Changwen Yang, Qian Yao, Xuewei Du, Shuai Ding, Yaoqiang Shi, Can Sheng, Ming Wang, Ying Han, Haiming Luo   +9 more
wiley   +1 more source

Exploring Knowledge and Awareness of Lewy Body Dementia Among Staff in Long-Term Care Facilities. [PDF]

J Multidiscip Healthc
Keane O, Fitzpatrick RL, Walsh S, Connelly JP, Leroi I.   +4 more
europepmc   +1 more source

Label‐Free Myelin Fingerprinting: An Adult Human Post‐Mortem Brain Slice Platform via Coherent Anti‐Stokes Raman Spectroscopy

Advanced Science, Volume 13, Issue 54, 28 September 2026.
A serum‐free, air–liquid interface organotypic slice culture model preserves human post‐mortem corpus callosum tissue, successfully recovering from slicing trauma to reflect the donor's underlying disease state. Pairing label‐free Coherent anti‐Stokes Raman scattering (CARS) microscopy with k‐means clustering enables objective, high‐resolution ...
Kasra Roya‐Kouchaki, Jeroen P. Korterik, Femke Tjebbes, Geert J. Schenk, Herman L. Offerhaus, Antonio Luchicchi   +5 more
wiley   +1 more source

α‐Synuclein Aggregate‐Disassembling Compounds Prolong Survival in a Mouse Model of Parkinson's Disease

Aggregate, Volume 7, Issue 9, September 2026.
All‐D peptides that bind monomeric α‐synuclein shift the aggregation equilibrium, dismantle pathogenic fibrils, and suppress seeding activity in vitro and in cells. In a Parkinson's disease mouse model, treatment delays disease progression and extends survival, supporting direct aggregate disassembly as a disease‐modifying therapeutic strategy for ...
Sara Reithofer, Marc Sevenich, Madita Vollmer, Dila Kurtul, Laura Müller, Pelin Özdüzenciler, Laurin Gerhards, Kira Allmeroth, Mathias Wendt, Fahimeh Charbgoo, Sarah Schemmert, Marcel Naumann, Karolina Korostov, Gina Hartmann, Lothar Gremer, Gültekin Tamgüney, Dieter Willbold, Antje Willuweit   +17 more
wiley   +1 more source